First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-06-29

AUTHORS

Todd Bauer, Byong Chul Cho, Rebecca Heist, Lyudmila Bazhenova, Theresa Werner, Sanjay Goel, Dong-Wan Kim, Douglas Adkins, Richard D. Carvajal, Ajjai Alva, Keith Eaton, Judy Wang, Yong Liu, Xiaohong Yan, Jamie Christensen, Saskia Neuteboom, Richard Chao, Shubham Pant

ABSTRACT

Sitravatinib (MGCD516), a spectrum-selective receptor tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MERTK) and split kinase family receptors, has demonstrated preclinical anti-tumor activity and modulation of tumor microenvironment. This first-in-human phase 1/1b study included sitravatinib dose exploration and anti-tumor activity evaluation in selected patients with advanced solid tumors. Primary objectives included assessment of safety, pharmacokinetics and clinical activity of sitravatinib. Secondary objectives included identifying doses for further investigation and exploring molecular markers for patient selection. In phase 1, 32 patients received 10–200 mg, while phase 1b dose expansion comprised 161 patients (150 mg n = 99, 120 mg n = 62). Maximum tolerated dose was determined as 150 mg daily. Dose-limiting toxicity was reported in 4/28 evaluable phase 1 patients (three at 200 mg, one at 80 mg). In phase 1b, 120 mg was defined as the recommended dose due to tolerability. Treatment-related adverse events (TRAEs) were experienced by 174/193 patients (90.2%); grade ≥ 3 TRAEs in 103 patients (53.4%). Most common TRAEs were diarrhea, fatigue, hypertension and nausea; TRAEs led to treatment discontinuation in 26 patients (13.5%) and death in one patient. Sitravatinib was steadily absorbed and declined from plasma with a terminal elimination half-life of 42.1–51.5 h following oral administration. Overall objective response rate was 11.8% in phase 1b, 13.2% in patients with non-small cell lung cancer (NSCLC) and 4.2% in patients with NSCLC with prior checkpoint inhibitor experience. Sitravatinib demonstrated manageable safety and modest clinical activity in solid tumors. NCT02219711 (first posted August 14, 2014). More... »

PAGES

990-1000

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-022-01274-y

DOI

http://dx.doi.org/10.1007/s10637-022-01274-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1149064420

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35767205


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anilides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Microenvironment", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Drug Development, Sarah Cannon Research Institute, Tennessee Oncology, 250 25th Ave North, Ste 100, 37203, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.492963.3", 
          "name": [
            "Department of Drug Development, Sarah Cannon Research Institute, Tennessee Oncology, 250 25th Ave North, Ste 100, 37203, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bauer", 
        "givenName": "Todd", 
        "id": "sg:person.01343430002.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343430002.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yonsei University College of Medicine, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Yonsei University College of Medicine, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cho", 
        "givenName": "Byong Chul", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Massachusetts General Hospital, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.32224.35", 
          "name": [
            "Massachusetts General Hospital, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heist", 
        "givenName": "Rebecca", 
        "id": "sg:person.0610455100.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610455100.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California San Diego, Moores Cancer Center, La Jolla, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.516081.b", 
          "name": [
            "University of California San Diego, Moores Cancer Center, La Jolla, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bazhenova", 
        "givenName": "Lyudmila", 
        "id": "sg:person.01252506611.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252506611.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA", 
          "id": "http://www.grid.ac/institutes/grid.479969.c", 
          "name": [
            "Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Werner", 
        "givenName": "Theresa", 
        "id": "sg:person.01105332167.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105332167.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.240283.f", 
          "name": [
            "Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goel", 
        "givenName": "Sanjay", 
        "id": "sg:person.0732217350.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732217350.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea", 
          "id": "http://www.grid.ac/institutes/grid.31501.36", 
          "name": [
            "Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kim", 
        "givenName": "Dong-Wan", 
        "id": "sg:person.01025773275.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025773275.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Washington University, St. Louis, MO, USA", 
          "id": "http://www.grid.ac/institutes/grid.4367.6", 
          "name": [
            "Washington University, St. Louis, MO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adkins", 
        "givenName": "Douglas", 
        "id": "sg:person.013732120737.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013732120737.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Columbia University Irving Medical Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239585.0", 
          "name": [
            "Columbia University Irving Medical Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D.", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Michigan Medical Center, Ann Arbor, MI, USA", 
          "id": "http://www.grid.ac/institutes/grid.412590.b", 
          "name": [
            "University of Michigan Medical Center, Ann Arbor, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alva", 
        "givenName": "Ajjai", 
        "id": "sg:person.01262016125.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262016125.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington, Seattle, WA, USA", 
          "id": "http://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "University of Washington, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eaton", 
        "givenName": "Keith", 
        "id": "sg:person.01077303351.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077303351.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sarah Cannon Research Institute, Florida Cancer Specialists, Sarasota, FL, USA", 
          "id": "http://www.grid.ac/institutes/grid.428633.8", 
          "name": [
            "Sarah Cannon Research Institute, Florida Cancer Specialists, Sarasota, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Judy", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mirati Therapeutics, Inc, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.421297.b", 
          "name": [
            "Mirati Therapeutics, Inc, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Yong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mirati Therapeutics, Inc, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.421297.b", 
          "name": [
            "Mirati Therapeutics, Inc, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yan", 
        "givenName": "Xiaohong", 
        "id": "sg:person.014773601427.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014773601427.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mirati Therapeutics, Inc, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.421297.b", 
          "name": [
            "Mirati Therapeutics, Inc, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Christensen", 
        "givenName": "Jamie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mirati Therapeutics, Inc, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.421297.b", 
          "name": [
            "Mirati Therapeutics, Inc, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neuteboom", 
        "givenName": "Saskia", 
        "id": "sg:person.0667752115.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667752115.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mirati Therapeutics, Inc, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.421297.b", 
          "name": [
            "Mirati Therapeutics, Inc, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chao", 
        "givenName": "Richard", 
        "id": "sg:person.01212235774.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212235774.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pant", 
        "givenName": "Shubham", 
        "id": "sg:person.0740650156.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740650156.03"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1479-5876-5-32", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001875982", 
          "https://doi.org/10.1186/1479-5876-5-32"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3627", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011267322", 
          "https://doi.org/10.1038/nrc3627"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12967-015-0747-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002728002", 
          "https://doi.org/10.1186/s12967-015-0747-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-015-2779-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040534451", 
          "https://doi.org/10.1007/s00280-015-2779-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-06-29", 
    "datePublishedReg": "2022-06-29", 
    "description": "Sitravatinib (MGCD516), a spectrum-selective receptor tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MERTK) and split kinase family receptors, has demonstrated preclinical anti-tumor activity and modulation of tumor microenvironment. This first-in-human phase 1/1b study included sitravatinib dose exploration and anti-tumor activity evaluation in selected patients with advanced solid tumors. Primary objectives included assessment of safety, pharmacokinetics and clinical activity of sitravatinib. Secondary objectives included identifying doses for further investigation and exploring molecular markers for patient selection. In phase 1, 32 patients received 10\u2013200 mg, while phase 1b dose expansion comprised 161 patients (150 mg n = 99, 120 mg n = 62). Maximum tolerated dose was determined as 150 mg daily. Dose-limiting toxicity was reported in 4/28 evaluable phase 1 patients (three at 200 mg, one at 80 mg). In phase 1b, 120 mg was defined as the recommended dose due to tolerability. Treatment-related adverse events (TRAEs) were experienced by 174/193 patients (90.2%); grade \u2265 3 TRAEs in 103 patients (53.4%). Most common TRAEs were diarrhea, fatigue, hypertension and nausea; TRAEs led to treatment discontinuation in 26 patients (13.5%) and death in one patient. Sitravatinib was steadily absorbed and declined from plasma with a terminal elimination half-life of 42.1\u201351.5 h following oral administration. Overall objective response rate was 11.8% in phase 1b, 13.2% in patients with non-small cell lung cancer (NSCLC) and 4.2% in patients with NSCLC with prior checkpoint inhibitor experience. Sitravatinib demonstrated manageable safety and modest clinical activity in solid tumors. NCT02219711 (first posted August 14, 2014).", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-022-01274-y", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "40"
      }
    ], 
    "keywords": [
      "treatment-related adverse events", 
      "non-small cell lung cancer", 
      "phase 1/1b study", 
      "advanced solid tumors", 
      "solid tumors", 
      "clinical activity", 
      "Most common treatment-related adverse events", 
      "common treatment-related adverse events", 
      "phase 1b", 
      "overall objective response rate", 
      "preclinical anti-tumor activity", 
      "anti-tumor activity evaluation", 
      "receptor tyrosine kinase inhibitors", 
      "phase 1 patients", 
      "objective response rate", 
      "modest clinical activity", 
      "cell lung cancer", 
      "tyrosine kinase inhibitors", 
      "anti-tumor activity", 
      "assessment of safety", 
      "dose expansion", 
      "treatment discontinuation", 
      "adverse events", 
      "manageable safety", 
      "terminal elimination", 
      "patient selection", 
      "lung cancer", 
      "sitravatinib", 
      "oral administration", 
      "patients", 
      "response rate", 
      "secondary objective", 
      "tumor microenvironment", 
      "kinase inhibitors", 
      "family receptors", 
      "tumors", 
      "dose", 
      "further investigation", 
      "phase 1", 
      "primary objective", 
      "activity evaluation", 
      "safety", 
      "tolerability", 
      "hypertension", 
      "nausea", 
      "discontinuation", 
      "diarrhea", 
      "pharmacokinetics", 
      "cancer", 
      "doses", 
      "administration", 
      "activity", 
      "receptors", 
      "death", 
      "molecular markers", 
      "inhibitors", 
      "markers", 
      "study", 
      "toxicity", 
      "microenvironment", 
      "grade", 
      "fatigue", 
      "objective", 
      "assessment", 
      "modulation", 
      "TAM", 
      "plasma", 
      "evaluation", 
      "elimination", 
      "rate", 
      "events", 
      "experience", 
      "investigation", 
      "exploration", 
      "selection", 
      "expansion", 
      "maximum"
    ], 
    "name": "First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors", 
    "pagination": "990-1000", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1149064420"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-022-01274-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35767205"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-022-01274-y", 
      "https://app.dimensions.ai/details/publication/pub.1149064420"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_939.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-022-01274-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-022-01274-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-022-01274-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-022-01274-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-022-01274-y'


 

This table displays all metadata directly associated to this object as RDF triples.

336 TRIPLES      21 PREDICATES      113 URIs      101 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-022-01274-y schema:about N036cbed34b7c428086904d8e045fb5b4
2 N037c3f253fe54081833f7bc05845b804
3 N36ccbefbb5f7467f90ead34d8867778a
4 N53f695e692e1428aaf1b1d37a2efce3a
5 N67b33660485245de824dcc9f8774e3da
6 N76d50a6f9dbe43e19afd133671779f3a
7 Nd3c3c2ddd8ee4a6eb6a3d678822de7f3
8 anzsrc-for:11
9 anzsrc-for:1112
10 schema:author Nf03b0d369ec24942902bbd5fbcd16440
11 schema:citation sg:pub.10.1007/s00280-015-2779-7
12 sg:pub.10.1038/nrc3627
13 sg:pub.10.1186/1479-5876-5-32
14 sg:pub.10.1186/s12967-015-0747-y
15 schema:datePublished 2022-06-29
16 schema:datePublishedReg 2022-06-29
17 schema:description Sitravatinib (MGCD516), a spectrum-selective receptor tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MERTK) and split kinase family receptors, has demonstrated preclinical anti-tumor activity and modulation of tumor microenvironment. This first-in-human phase 1/1b study included sitravatinib dose exploration and anti-tumor activity evaluation in selected patients with advanced solid tumors. Primary objectives included assessment of safety, pharmacokinetics and clinical activity of sitravatinib. Secondary objectives included identifying doses for further investigation and exploring molecular markers for patient selection. In phase 1, 32 patients received 10–200 mg, while phase 1b dose expansion comprised 161 patients (150 mg n = 99, 120 mg n = 62). Maximum tolerated dose was determined as 150 mg daily. Dose-limiting toxicity was reported in 4/28 evaluable phase 1 patients (three at 200 mg, one at 80 mg). In phase 1b, 120 mg was defined as the recommended dose due to tolerability. Treatment-related adverse events (TRAEs) were experienced by 174/193 patients (90.2%); grade ≥ 3 TRAEs in 103 patients (53.4%). Most common TRAEs were diarrhea, fatigue, hypertension and nausea; TRAEs led to treatment discontinuation in 26 patients (13.5%) and death in one patient. Sitravatinib was steadily absorbed and declined from plasma with a terminal elimination half-life of 42.1–51.5 h following oral administration. Overall objective response rate was 11.8% in phase 1b, 13.2% in patients with non-small cell lung cancer (NSCLC) and 4.2% in patients with NSCLC with prior checkpoint inhibitor experience. Sitravatinib demonstrated manageable safety and modest clinical activity in solid tumors. NCT02219711 (first posted August 14, 2014).
18 schema:genre article
19 schema:isAccessibleForFree true
20 schema:isPartOf N28854999c20d403aa7f4388985051cee
21 N34d9e41c2d3f4638b16c1b80bab8d663
22 sg:journal.1094201
23 schema:keywords Most common treatment-related adverse events
24 TAM
25 activity
26 activity evaluation
27 administration
28 advanced solid tumors
29 adverse events
30 anti-tumor activity
31 anti-tumor activity evaluation
32 assessment
33 assessment of safety
34 cancer
35 cell lung cancer
36 clinical activity
37 common treatment-related adverse events
38 death
39 diarrhea
40 discontinuation
41 dose
42 dose expansion
43 doses
44 elimination
45 evaluation
46 events
47 expansion
48 experience
49 exploration
50 family receptors
51 fatigue
52 further investigation
53 grade
54 hypertension
55 inhibitors
56 investigation
57 kinase inhibitors
58 lung cancer
59 manageable safety
60 markers
61 maximum
62 microenvironment
63 modest clinical activity
64 modulation
65 molecular markers
66 nausea
67 non-small cell lung cancer
68 objective
69 objective response rate
70 oral administration
71 overall objective response rate
72 patient selection
73 patients
74 pharmacokinetics
75 phase 1
76 phase 1 patients
77 phase 1/1b study
78 phase 1b
79 plasma
80 preclinical anti-tumor activity
81 primary objective
82 rate
83 receptor tyrosine kinase inhibitors
84 receptors
85 response rate
86 safety
87 secondary objective
88 selection
89 sitravatinib
90 solid tumors
91 study
92 terminal elimination
93 tolerability
94 toxicity
95 treatment discontinuation
96 treatment-related adverse events
97 tumor microenvironment
98 tumors
99 tyrosine kinase inhibitors
100 schema:name First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
101 schema:pagination 990-1000
102 schema:productId N75b7f08cfe7a4278abd4d872dada57b9
103 Na64b77817cf445d88e07fe614288bed3
104 Ncfa870ebfe1a44c6a55feaba0c8d3a36
105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1149064420
106 https://doi.org/10.1007/s10637-022-01274-y
107 schema:sdDatePublished 2022-12-01T06:44
108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
109 schema:sdPublisher Na4f90f07266b433f8b5be35184e04cea
110 schema:url https://doi.org/10.1007/s10637-022-01274-y
111 sgo:license sg:explorer/license/
112 sgo:sdDataset articles
113 rdf:type schema:ScholarlyArticle
114 N036cbed34b7c428086904d8e045fb5b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Tumor Microenvironment
116 rdf:type schema:DefinedTerm
117 N037c3f253fe54081833f7bc05845b804 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Carcinoma, Non-Small-Cell Lung
119 rdf:type schema:DefinedTerm
120 N052135764d9b47538780e3ea140605a7 rdf:first sg:person.01077303351.13
121 rdf:rest Nc843d532c79942148b8c59e040db739b
122 N1f0da351608e45d4ae094dec8abf9469 rdf:first sg:person.01262016125.18
123 rdf:rest N052135764d9b47538780e3ea140605a7
124 N28854999c20d403aa7f4388985051cee schema:issueNumber 5
125 rdf:type schema:PublicationIssue
126 N34d9e41c2d3f4638b16c1b80bab8d663 schema:volumeNumber 40
127 rdf:type schema:PublicationVolume
128 N36ccbefbb5f7467f90ead34d8867778a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Anilides
130 rdf:type schema:DefinedTerm
131 N3b6d16038b6c42c0a34e5dd554c8d2f7 schema:affiliation grid-institutes:grid.421297.b
132 schema:familyName Liu
133 schema:givenName Yong
134 rdf:type schema:Person
135 N3d3dddc2c7fe4c2ab7601292ea4985d9 rdf:first N6dc4d22ca10a407cabbe6a61636bf66b
136 rdf:rest N9ec9e40b071e4a7fbe81f26ca169b051
137 N3ff9eb8c72154644838d7d98bd2596d2 rdf:first sg:person.013732120737.09
138 rdf:rest N9187ecc40f8c4edc98982fe595c5bbd5
139 N465a16628f56403c9c0b7bede25cfba0 schema:affiliation grid-institutes:grid.421297.b
140 schema:familyName Christensen
141 schema:givenName Jamie
142 rdf:type schema:Person
143 N53f695e692e1428aaf1b1d37a2efce3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 N5a452ddb53b842e98b56f4dee26e1039 schema:affiliation grid-institutes:grid.428633.8
147 schema:familyName Wang
148 schema:givenName Judy
149 rdf:type schema:Person
150 N5f0baaf06ce44822a1f8c039c02eed61 rdf:first sg:person.0740650156.03
151 rdf:rest rdf:nil
152 N67b33660485245de824dcc9f8774e3da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Neoplasms
154 rdf:type schema:DefinedTerm
155 N6dc4d22ca10a407cabbe6a61636bf66b schema:affiliation grid-institutes:grid.15444.30
156 schema:familyName Cho
157 schema:givenName Byong Chul
158 rdf:type schema:Person
159 N75b7f08cfe7a4278abd4d872dada57b9 schema:name doi
160 schema:value 10.1007/s10637-022-01274-y
161 rdf:type schema:PropertyValue
162 N76d50a6f9dbe43e19afd133671779f3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Lung Neoplasms
164 rdf:type schema:DefinedTerm
165 N78d2ae88f06b4b8f81da491c1af57969 rdf:first sg:person.0732217350.00
166 rdf:rest Nb6898d6d96ef47759b19f3ae6cbfb2e3
167 N9187ecc40f8c4edc98982fe595c5bbd5 rdf:first sg:person.0726366600.25
168 rdf:rest N1f0da351608e45d4ae094dec8abf9469
169 N97e96535fddf44509acb32943fe51748 rdf:first sg:person.01212235774.64
170 rdf:rest N5f0baaf06ce44822a1f8c039c02eed61
171 N9ec9e40b071e4a7fbe81f26ca169b051 rdf:first sg:person.0610455100.85
172 rdf:rest Ndaa834e9a87347d296ae3ab65dc12706
173 Na4f90f07266b433f8b5be35184e04cea schema:name Springer Nature - SN SciGraph project
174 rdf:type schema:Organization
175 Na64b77817cf445d88e07fe614288bed3 schema:name dimensions_id
176 schema:value pub.1149064420
177 rdf:type schema:PropertyValue
178 Naa221e0cb0dd4fd582a65ad90309d77e rdf:first sg:person.0667752115.95
179 rdf:rest N97e96535fddf44509acb32943fe51748
180 Nb6898d6d96ef47759b19f3ae6cbfb2e3 rdf:first sg:person.01025773275.27
181 rdf:rest N3ff9eb8c72154644838d7d98bd2596d2
182 Nc62df3b39cc841d4bae7f4373f8fe586 rdf:first N465a16628f56403c9c0b7bede25cfba0
183 rdf:rest Naa221e0cb0dd4fd582a65ad90309d77e
184 Nc843d532c79942148b8c59e040db739b rdf:first N5a452ddb53b842e98b56f4dee26e1039
185 rdf:rest Nd6fc3c05f93a42e5aca1f6767c7ab81c
186 Ncfa870ebfe1a44c6a55feaba0c8d3a36 schema:name pubmed_id
187 schema:value 35767205
188 rdf:type schema:PropertyValue
189 Nd3c3c2ddd8ee4a6eb6a3d678822de7f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Pyridines
191 rdf:type schema:DefinedTerm
192 Nd6fc3c05f93a42e5aca1f6767c7ab81c rdf:first N3b6d16038b6c42c0a34e5dd554c8d2f7
193 rdf:rest Ne3ce469167ef44e3ba48a87e139d7074
194 Ndaa834e9a87347d296ae3ab65dc12706 rdf:first sg:person.01252506611.29
195 rdf:rest Nf47bb996612448b5a7bb05c29a443fb0
196 Ne3ce469167ef44e3ba48a87e139d7074 rdf:first sg:person.014773601427.69
197 rdf:rest Nc62df3b39cc841d4bae7f4373f8fe586
198 Nf03b0d369ec24942902bbd5fbcd16440 rdf:first sg:person.01343430002.75
199 rdf:rest N3d3dddc2c7fe4c2ab7601292ea4985d9
200 Nf47bb996612448b5a7bb05c29a443fb0 rdf:first sg:person.01105332167.37
201 rdf:rest N78d2ae88f06b4b8f81da491c1af57969
202 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
203 schema:name Medical and Health Sciences
204 rdf:type schema:DefinedTerm
205 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
206 schema:name Oncology and Carcinogenesis
207 rdf:type schema:DefinedTerm
208 sg:journal.1094201 schema:issn 0167-6997
209 1573-0646
210 schema:name Investigational New Drugs
211 schema:publisher Springer Nature
212 rdf:type schema:Periodical
213 sg:person.01025773275.27 schema:affiliation grid-institutes:grid.31501.36
214 schema:familyName Kim
215 schema:givenName Dong-Wan
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025773275.27
217 rdf:type schema:Person
218 sg:person.01077303351.13 schema:affiliation grid-institutes:grid.34477.33
219 schema:familyName Eaton
220 schema:givenName Keith
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077303351.13
222 rdf:type schema:Person
223 sg:person.01105332167.37 schema:affiliation grid-institutes:grid.479969.c
224 schema:familyName Werner
225 schema:givenName Theresa
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105332167.37
227 rdf:type schema:Person
228 sg:person.01212235774.64 schema:affiliation grid-institutes:grid.421297.b
229 schema:familyName Chao
230 schema:givenName Richard
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01212235774.64
232 rdf:type schema:Person
233 sg:person.01252506611.29 schema:affiliation grid-institutes:grid.516081.b
234 schema:familyName Bazhenova
235 schema:givenName Lyudmila
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252506611.29
237 rdf:type schema:Person
238 sg:person.01262016125.18 schema:affiliation grid-institutes:grid.412590.b
239 schema:familyName Alva
240 schema:givenName Ajjai
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01262016125.18
242 rdf:type schema:Person
243 sg:person.01343430002.75 schema:affiliation grid-institutes:grid.492963.3
244 schema:familyName Bauer
245 schema:givenName Todd
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343430002.75
247 rdf:type schema:Person
248 sg:person.013732120737.09 schema:affiliation grid-institutes:grid.4367.6
249 schema:familyName Adkins
250 schema:givenName Douglas
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013732120737.09
252 rdf:type schema:Person
253 sg:person.014773601427.69 schema:affiliation grid-institutes:grid.421297.b
254 schema:familyName Yan
255 schema:givenName Xiaohong
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014773601427.69
257 rdf:type schema:Person
258 sg:person.0610455100.85 schema:affiliation grid-institutes:grid.32224.35
259 schema:familyName Heist
260 schema:givenName Rebecca
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610455100.85
262 rdf:type schema:Person
263 sg:person.0667752115.95 schema:affiliation grid-institutes:grid.421297.b
264 schema:familyName Neuteboom
265 schema:givenName Saskia
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667752115.95
267 rdf:type schema:Person
268 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.239585.0
269 schema:familyName Carvajal
270 schema:givenName Richard D.
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
272 rdf:type schema:Person
273 sg:person.0732217350.00 schema:affiliation grid-institutes:grid.240283.f
274 schema:familyName Goel
275 schema:givenName Sanjay
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732217350.00
277 rdf:type schema:Person
278 sg:person.0740650156.03 schema:affiliation grid-institutes:grid.240145.6
279 schema:familyName Pant
280 schema:givenName Shubham
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740650156.03
282 rdf:type schema:Person
283 sg:pub.10.1007/s00280-015-2779-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040534451
284 https://doi.org/10.1007/s00280-015-2779-7
285 rdf:type schema:CreativeWork
286 sg:pub.10.1038/nrc3627 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011267322
287 https://doi.org/10.1038/nrc3627
288 rdf:type schema:CreativeWork
289 sg:pub.10.1186/1479-5876-5-32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001875982
290 https://doi.org/10.1186/1479-5876-5-32
291 rdf:type schema:CreativeWork
292 sg:pub.10.1186/s12967-015-0747-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1002728002
293 https://doi.org/10.1186/s12967-015-0747-y
294 rdf:type schema:CreativeWork
295 grid-institutes:grid.15444.30 schema:alternateName Yonsei University College of Medicine, Seoul, Republic of Korea
296 schema:name Yonsei University College of Medicine, Seoul, Republic of Korea
297 rdf:type schema:Organization
298 grid-institutes:grid.239585.0 schema:alternateName Columbia University Irving Medical Center, New York, NY, USA
299 schema:name Columbia University Irving Medical Center, New York, NY, USA
300 rdf:type schema:Organization
301 grid-institutes:grid.240145.6 schema:alternateName University of Texas MD Anderson Cancer Center, Houston, TX, USA
302 schema:name University of Texas MD Anderson Cancer Center, Houston, TX, USA
303 rdf:type schema:Organization
304 grid-institutes:grid.240283.f schema:alternateName Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA
305 schema:name Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA
306 rdf:type schema:Organization
307 grid-institutes:grid.31501.36 schema:alternateName Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea
308 schema:name Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea
309 rdf:type schema:Organization
310 grid-institutes:grid.32224.35 schema:alternateName Massachusetts General Hospital, Boston, MA, USA
311 schema:name Massachusetts General Hospital, Boston, MA, USA
312 rdf:type schema:Organization
313 grid-institutes:grid.34477.33 schema:alternateName University of Washington, Seattle, WA, USA
314 schema:name University of Washington, Seattle, WA, USA
315 rdf:type schema:Organization
316 grid-institutes:grid.412590.b schema:alternateName University of Michigan Medical Center, Ann Arbor, MI, USA
317 schema:name University of Michigan Medical Center, Ann Arbor, MI, USA
318 rdf:type schema:Organization
319 grid-institutes:grid.421297.b schema:alternateName Mirati Therapeutics, Inc, San Diego, CA, USA
320 schema:name Mirati Therapeutics, Inc, San Diego, CA, USA
321 rdf:type schema:Organization
322 grid-institutes:grid.428633.8 schema:alternateName Sarah Cannon Research Institute, Florida Cancer Specialists, Sarasota, FL, USA
323 schema:name Sarah Cannon Research Institute, Florida Cancer Specialists, Sarasota, FL, USA
324 rdf:type schema:Organization
325 grid-institutes:grid.4367.6 schema:alternateName Washington University, St. Louis, MO, USA
326 schema:name Washington University, St. Louis, MO, USA
327 rdf:type schema:Organization
328 grid-institutes:grid.479969.c schema:alternateName Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA
329 schema:name Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA
330 rdf:type schema:Organization
331 grid-institutes:grid.492963.3 schema:alternateName Department of Drug Development, Sarah Cannon Research Institute, Tennessee Oncology, 250 25th Ave North, Ste 100, 37203, Nashville, TN, USA
332 schema:name Department of Drug Development, Sarah Cannon Research Institute, Tennessee Oncology, 250 25th Ave North, Ste 100, 37203, Nashville, TN, USA
333 rdf:type schema:Organization
334 grid-institutes:grid.516081.b schema:alternateName University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
335 schema:name University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
336 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...